ACHE and Alzheimer disease: The phase III clinical trial is currently assessing the efficacy of hydralazine in early-stage AD patients who take one of the acetylcholinesterase inhibitors (AChEI), donepezil, rivastigmine, or galantamine (clinicaltrials.gov: NCT04842552).